


Adverse Drug Reaction Reporting Form

A. Patient Information				C. Suspect Medication			D. Reporter				
1. Patient Initials: _____	3. Sex: _____	4. Height: _____	5. Weight: _____	13. Name (Brand and Generic) # 1 _____ # 2 _____	14. Strength* # 1 _____ # 2 _____	15. Manufacturer* # 1 _____ # 2 _____	24. Event reoccurred after reintroduction of suspect medication <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA	25. Concomitant medicinal products:			
2. Age: _____ or Date of Birth: _____ (dd/mm/yyyy)	<input type="checkbox"/> Male <input type="checkbox"/> Female	_____ cm	_____ kg	* from product label	17. Frequency # 1 _____ # 2 _____	18. Route Used # 1 _____ # 2 _____	26. Outcome of the event: <input type="checkbox"/> Fatal <input type="checkbox"/> Recovered <input type="checkbox"/> Other (specify) <input type="checkbox"/> Recovering <input type="checkbox"/> Unknown				
B. Adverse Event											
7. Seriousness of the event:											
<input type="checkbox"/> Death <input type="checkbox"/> Required intervention to prevent permanent impairment/damage											
<input type="checkbox"/> Hospitalization- initial or prolonged <input type="checkbox"/> Disability											
<input type="checkbox"/> Congenital anomaly <input type="checkbox"/> Life threatening											
8. Date of Event: _____ (dd/mm/yyyy)					9. Date of this report: _____ (dd/mm/yyyy)						
10. Describe event or problem:											
11. Relevant tests/laboratory data (attach memo, if required):											
12. Other relevant history, including pre-existing medical conditions (e.g. allergy, pregnancy, smoking and alcohol use, hepatic/renal dysfunction etc.):											
19. Therapy dates:					20. Batch			21. Expiry Date		22. Indication	
Start Date (dd/mm/yyyy)			End Date (dd/mm/yyyy)			Duration			# 1 _____		
# 1 _____			# 2 _____			# 1 _____			# 2 _____		
# 2 _____			# 1 _____			# 2 _____			# 1 _____		
# 2 _____			# 1 _____			# 2 _____			# 2 _____		
23. Event abated after discontinuation of suspect medication <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA											
D. Reporter											
27. Name and address:											
28. Phone:			29. E-mail:			30. Fax:					
31. Healthcare Professional: <input type="checkbox"/> Yes <input type="checkbox"/> No											
32. Occupation:											
33. Also reported to: <input type="checkbox"/> Regulatory agencies <input type="checkbox"/> Distributor/sales personnel											

Processing of Individual Case Safety Reports [SOP-GV-001]		Approved by	Dr. Rajul Rastogi	
Annexure / Version	03 / 02	Effective Date	17 July 2020	
Page	01 of 2			

CONFIDENTIALITY

Any information related to the identities of the reporter and patient will be kept confidential.

- **Report SERIOUS adverse events. An event is serious when the patient outcome is:**

- Death
- Life-threatening (real risk of dying)
- Hospitalization (initial or prolonged)
- Disability (significant, persistent or permanent)
- Congenital anomaly
- Required intervention to prevent permanent impairment

Medical events that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed above shall also be considered as serious events.

- **Report even if:**

- You're not certain the product caused adverse experience
- You don't have all the details although point nos. 1, 7, 8, 9, 10, 11, 13 & 27 are essentially required

HOW TO REPORT

- Just fill in the sections that apply to your report
- Attach additional pages if needed. Use a separate form for each patient and event

WHERE TO REPORT

Mail to:

**Global Vigilance – Vigilance Competence Centre
Fresenius Kabi Oncology Limited
Echelon Institutional Area,
Plot No. 11,
Sec 32 Gurgaon 122001**




Fax: +91-124-3325003



Phone: +91-124-4885000 (Extn. 5227 / 5228 / 5234 / 5165 / 5163)



E-mail: Covigilancecell.IN_ND@fresenius-kabi.com

Processing of Individual Case Safety Reports [SOP-GV-001]		Approved by	Dr. Rajul Rastogi	
Annexure / Version	03 / 02	Effective Date	17 July 2020	
Page	02 of 2			